NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01971658,Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04),https://clinicaltrials.gov/study/NCT01971658,IFM2013-04,COMPLETED,"This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib) Cyclophosphamide Dexamethasone (VCD) as an Induction Treatment prior to Autologous Stem Cell Transplantation in patients with Newly Diagnosed Multiple Myeloma.

Eligible patients will be randomized into 2 treatment arms. Each patient will receive 4 consecutive 21 day cycles of an induction treatment with either VTD or VCD.",NO,Multiple Myeloma,DRUG: Thalidomide®|DRUG: Cyclophosphamide|DRUG: Velcade®|DRUG: Dexaméthasone,"Response assessment according to the criteria IMWG, compare the Response assessment in both arms: the Very good partial remission rate (according to the criteria IMWG) achieved with four courses of VTD with that achieved with four courses of VCD, 15-17 month","Response assessment according to the criteria IMWG, compare the Response assessment in both arms: the following parameters after induction treatment with four courses of VTD or four courses of VCD the Complete remission rate (according to the criteria IMWG), 15 - 17 month|Number of Adverse Events, To evaluate the Safety of induction therapy, 15-17 month|Number of collected stem cell, 17 month|Number of death, To evaluate Overall and Progression-Free Survival, 17 month|Response assessment according to the criteria IMWG, compare the Response assessment in both arms: Compare the following parameters after induction treatment with four courses of VTD or four courses of VCD the Partial remission rate (according to the criteria IMWG), 15-17 month|Number of relapse according to the criteria IMWG, Progression-Free Survival, 17 month","Comparison of three techniques for the quantification of urinary monoclonal components in patients with Newly Diagnosed Multiple Myeloma., The detection and the estimation of the urinary monoclonal components is an inescapable element of the diagnosis and the evaluation of the therapeutic efficacy in the myeloma.

Urinary protein, electrophoresisin agarose gel is the quantitative method of choice. In these labs, the quantification of the urinary monoclonal peak is not performed. In the absence of quantitative data on urinary monoclonal components, the patient is considered as non-assessable. Recently, the company Sebia has developed the quantification on two other materials used specifically for the characterization of monoclonal component and / or proteinuria (HYDRAGEL BENCE JONES and HYDRAGEL URINE PROFILE).

The objective of this study is to compare the quantification of monoclonal components between the reference HR electrophoresis technique and the other two above-mentioned techniques., 17 month",Nantes University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,358,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,RC13_0284|2013-003174-27,2013-10,2015-08,2015-08,2013-10-29,,2015-10-07,"Centre Hospitalier de la région d'Annecy, Annecy, Pringy, 74374, France|CHRU Hôpital Sud, Amiens, 80054, France|CHU Angers, Angers, 49033, France|Centre Hospitalier Argenteuil, Argenteuil, 95 100, France|Centre Hospitalier H.Duffaut, Avignon, 84902, France|Centre Hospitalier de la Côte Basque, Bayonne, 64109, France|CHRU de Besançon, Besançon, 25030, France|Hôpital Avicenne, Bobigny, 93009, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33 300, France|Centre hospitalier Pierre Oudot, Bourgoin Jallieu, 38300, France|Hôpital A.Morvan, Brest, 29609, France|CHU Caen Côte de Nacre, Caen, 14033, France|CH René Dubos, Cergy-pontoise, 95303, France|Centre Hospitalier William Morey, Chalon/saone, 71 321, France|Hôpital d'instruction des armées Percy, Clamart, 92141, France|CHU d'Estaing, Clermont-ferrand, 63000, France|Hôpitaux civils de Colmar, Colmar, 68024, France|Centre Hospitalier Sud Francilien, Corbeil-essonnes, 91100, France|CHU Henri Mondor, Creteil, 94 010, France|CHRU Dijon, Dijon, 21000, France|Centre Hospitalier Général, Dunkerque, 59 385, France|CHRU - Hôpital A.Michallon, Grenoble, 38043, France|Centre hospitalier départemental Vendée, La Roche Sur Yon, 85925, France|Hôpital Louis Pasteur, Le Coudray, 28000, France|Centre Jean Bernard, Le Mans, 72000, France|CH Le Mans, Le Mans, 72000, France|Hopital Saint Vincent de Paul, Lille, 59020, France|CHRU - Hôpital Claude Huriez, Lille, 59037, France|CHU de Limoges, Limoges, 87042, France|Hôpital Du Scorff, Lorient, 56100, France|Centre Léon Bérard, Lyon, 69008, France|Institut Paoli Calmettes, Marseille, 13273, France|Centre Hospitalier de Meaux, Meaux, 77104, France|CHR Metz Thionville, Metz, 57085, France|Centre Hospitalier intercommunale Meulan les mureaux, Meulan, 78250, France|Hopital E Muller, Mulhouse, 68100, France|Nantes University Hospital, Nantes, 44093, France|Hôpital de l'Archet 1, Nice, 06202, France|Groupe Hospitalo-Universitaire Carémeau, Nimes, 30029, France|CHU - Hôpital St-Antoine, PARIS cedex 12, 75571, France|Institut CURIE, Paris, 75005, France|Hôpital Cochin, Paris, 75014, France|CHU - Hôpital St-Antoine, Paris, 75571, France|Hôpital Pitié-Salpétrière, Paris, 75651, France|AP-HP Hôpital Necker, Paris, 75743, France|Centre Hospitalier de PERIGUEUX, Perigueux, 24000, France|CH Saint Jean, Perpignan, 66046, France|CHRU - Hôpital du Haut Lévêque, Pessac, 33604, France|Centre Hospitalier Lyon sud, Pierre Benite, 69495, France|CHRU - Hôpital Jean Bernard, Poitiers, 86021, France|Hôpital R.Debré, Reims, 51092, France|CHRU - Hôpital de Pontchaillou, Rennes, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|Centre Hospitalier, Saint Quentin, 02 321, France|Centre Hospitalier Yves le Foll, St Brieuc, 22 027, France|Centre René Huguenin, St Cloud, 92210, France|Centre hospitalier, ST Malo, 35400, France|Institut de Cancérologie de la Loire, St Priest-en-jarez, 42 271, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, 67091, France|CHRU - Hôpital Purpan, Toulouse, 31059, France|CHRU - Hôpital Bretonneau, Tours, 37044, France|CHRU - Hôpitaux de Brabois, Vandoeuvre Les Nancy, 54511, France|CH Bretagne Atlantique Vannes et Auray, Vannes, 56017, France",
